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From eﬃ  cacy to pragmatic trials: does the dodo bird 
verdict apply?
“Everybody has won, so all shall have prizes”, 
concluded the dodo bird in Alice in Wonderland upon 
judging a race. Despite advances in treatment and 
the science upon which our treatments are built, the 
question of whether the dodo bird verdict continues to 
apply to our psychotherapy evidence1 is emphasised by 
results of Ian Goodyer and colleagues’ IMPACT trial in 
The Lancet Psychiatry.2
This pragmatic randomised controlled superiority 
trial compares three treatments in adolescents with 
unipolar major depressive disorder as delivered across 
diverse specialist mental health clinics in the UK 
health system: cognitive behavioural therapy (CBT), 
short-term psychoanalytical psychotherapy, and 
brief psychological intervention—the comparator 
treatment. Results indicate improvements over time for 
all three treatment conditions. However, the primary 
outcome of self-reported depressive symptoms, 
measured with the Mood and Feelings Questionnaire, 
did not diﬀ er signiﬁ cantly between groups at 36, 52, 
or 86 weeks post-randomisation, nor did the two 
hypothesised eﬀ ective treatments (CBT and short-term 
psychoanalytical psychotherapy) lead to signiﬁ cantly 
greater beneﬁ ts compared with the brief psychological 
intervention. Total costs of the trial interventions did not 
diﬀ er signiﬁ cantly between groups.
These results give the ﬁ eld a well needed jolt. Research 
advances have sparked eﬀ orts to move from bench to 
bedside and implement evidence-based treatments to 
improve patient outcomes. The long delays between 
scientiﬁ c discoveries and translation into clinical practice 
have been tackled through various mechanisms, including 
systematic reviews, evidence-based treatment registries, 
and policies that encourage or incentivise evidence-
based treatments.3 Yet results of this pragmatic trial 
point to similar eﬀ ectiveness of three diﬀ erent treatment 
strategies varying in levels of supporting evidence.
CBT for depression has strong supporting evidence and 
is considered a well established treatment for adolescents 
with depression.3–5 Evidence is weaker for short-term 
psychoanalytical psychotherapy; to our knowledge, no 
randomised controlled trial has shown the eﬃ  cacy of 
this intervention relative to a control or comparator 
condition in adolescents with depression.2,6 In the 
IMPACT trial, the brief psychological intervention was 
delivered mostly by psychiatrists (84%), included known 
active treatment components from CBTs (eg, problem 
solving, encouragement of pleasant activities), and 
when combined with ﬂ uoxetine yielded eﬀ ects similar to 
those noted for CBT, ﬂ uoxetine, and brief psychological 
intervention combined at 28 weeks in a previous 
study.7 The results of IMPACT raise questions about 
the eﬀ ectiveness of all three treatments (combined 
with SSRIs in 36–41% of adolescents in each treatment 
group), and suggest that most psychotherapies will be 
“winners” on the basis of non-speciﬁ c treatment factors, 
or alternatively that each treatment might contain 
distinct speciﬁ c factors that contribute to recovery.
One caveat to consider in this trial is that passage of 
time might have accounted for improvements in clinical 
symptoms. The morbidity of adolescent depression 
ethically precludes a no-treatment comparator, but 
most major depressive episodes resolve over time, with 
recovery estimates as high as 90–100%.8–10 Although 
risk of relapse or recurrence (the study target) is high 
and estimated to be as high as 71%,9,10 the study 
endpoint (86 weeks post-randomisation, 52 weeks 
post-treatment) might have been too short to detect 
these eﬀ ects.8
Pragmatic trials, such as IMPACT, evaluate treatments 
as delivered in routine practice, allowing for additions 
to the therapy under investigation—eg, treatment 
protocols, manuals, and treatment adherence 
monitoring. Treatment dose, training, and quality 
assurance protocols are often weaker in these trials 
than in highly controlled eﬃ  cacy trials.3 Indeed, CBT 
adherence in IMPACT was modest relative to that 
for eﬃ  cacy trials (74% of IMPACT CBT sessions met 
ﬁ delity criteria vs 94–95% in the TORDIA study4), and 
the treatment adherence measure was not designed 
speciﬁ cally for CBT. Although the tight control in eﬃ  cacy 
trials done in highly controlled (often laboratory) 
settings, with rigorous therapist training and quality 
assurance monitoring, is crucial for identiﬁ cation of 
active treatment components and mechanisms, these 
controls are not generally achievable in routine specialist 
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mental health clinics.3 What really matters to individuals 
living with depression is the beneﬁ ts of treatments 
available in their clinics. Unfortunately, treatments 
as delivered in routine mental health settings and 
pragmatic trials might be less eﬀ ective than in 
laboratory-based eﬃ  cacy trials, with evidence pointing 
to stronger treatment eﬀ ects when more eﬃ  cacy design 
components are present.3,11
Cross-national variability could also account for some 
diﬀ erences between the IMPACT results and those of 
US trials in which CBT has frequently, but not always, 
shown advantages over strong comparator conditions, 
such as supportive therapy or family therapy.3–5,10 
Variation exists across types of CBT for depression, 
and site diﬀ erences are common in trials of depression 
treatment,12 although are not apparent in the present 
study. The CBT given in IMPACT might have been 
less eﬀ ective than that used in trials demonstrating 
eﬃ  cacy. Review of the IMPACT adherence scales and 
CBT manual suggests that, compared with other types 
of CBT, the IMPACT model was more didactic, less 
youth friendly, and might have had less emphasis on 
elements viewed as preconditions for CBT eﬃ  cacy 
(eg, therapist active listening and observation, 
collaborative agenda setting).4,8
The IMPACT trial advances our knowledge and 
highlights directions for future research. If many of our 
treatments are “winners,” then a key task is to identify the 
elements that contribute to this common eﬀ ectiveness. 
In our enthusiasm for translation of science to clinical 
practice, we might have overemphasised evidence-based 
treatments and not attended suﬃ  ciently to treatment 
processes that lead to eﬃ  cacy of diverse treatments, 
such as the therapeutic alliance or monitoring of patient 
outcomes or using tools such as clinical dashboards to 
guide evidence-based decision making. Identiﬁ cation 
of treatments and treatment elements with minimal 
adverse eﬀ ects is also important, and many adolescents 
continue to report depressive symptoms despite 
diagnostic remission in IMPACT and other trials.2,10 
Consistent with personalised medicine, tailoring of 
treatments for individual young people might be crucial 
to achievement of optimal beneﬁ ts. Genetic, hormonal, 
brain-imaging, stress, and other forthcoming data 
from the IMPACT trial will enable analyses exploring 
variation and mechanisms of treatment response, 
enhancing knowledge for personalised approaches and 
the innovative contributions of this study. Finally, more 
research aimed at understanding key elements and 
mechanisms contributing to treatment eﬀ ectiveness are 
needed in both controlled and pragmatic trials before a 
ﬁ rm conclusion regarding the dodo bird verdict is applied.
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